Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

ATAD2 Drives Prostate Cancer Progression to Metastasis
Dutta, Anindita , Rodríguez-Calero, Antonio , Ronaldson-Bouchard, Kacey , Offermann, Anne , Rahman, Daoud , Vhatkar, Twinkle Bapuji , Hasson, Dan , Alshalalfa, Mohammed , Davicioni, Elai , Karnes, R. Jeffrey , Abate‐Shen, Cory , Rubin, Mark A , Vunjak-Novakovic, Gordana , Abate-Shen, Cory , Arriaga, Juan Martin , Davicioni, Elai , Offermann, Anne , Rubin, Mark A.

Molecular Cancer Research | February 5, 2025 | Volume: 23 | Issue: 5 | Pages: 379-390

10.1158/1541-7786.mcr-24-0544 | PMID 39907729 Get It

Abstract Metastasis accounts for the overwhelming majority of cancer deaths. In prostate cancer and many other solid tumors, progression to metastasis is associated with drastically reduced survival outcomes, yet the mechanisms behind this progression remain largely unknown. ATPase family AAA domain containing 2 (ATAD2) is an epigenetic reader of acetylated histones that is overexpressed in multiple cancer types and usually associated with poor patient outcomes. However, the functional role of ATAD2 in cancer progression and metastasis has been relatively understudied. Here, we employ genetically engineered mouse models of prostate cancer bone metastasis, as well as multiple independent human cohorts, to show that ATAD2 is highly enriched in bone metastasis compared with primary tumors and significantly associated with the development of metastasis. We show that ATAD2 expression is associated with MYC pathway activation in patient datasets and that, at least in a subset of tumors, MYC and ATAD2 can regulate each other’s expression. Using functional studies on mouse bone metastatic cell lines and innovative organ-on-a-chip bone invasion assays, we establish a functional role for ATAD2 inhibition in reducing prostate cancer metastasis and growth in bone. Implications: Our study highlights ATAD2 as a driver of prostate cancer progression and metastasis and suggests it may constitute a promising novel therapeutic target.
Genetic risk disclosure and behavioural change: not so fast
Naderian, Mohammadreza , Naderian, Mohammadreza , Kullo, Iftikhar J.

European Journal of Preventive Cardiology | February 5, 2025 | Volume: 33 | Issue: 3 | Pages: 338-340

10.1093/eurjpc/zwaf014 | PMID 39907735 Get It

Genomic Characterization of Chordoma: Insights from the AACR Project GENIE Database
Hsia, Beau, Bitar, Gabriel , Alshaka, Saif, Kim, Jeeho D. , Valencia‐Sanchez, Bastien A. , Brandel, Michael G. , Sato, Mariko , Levy, Michael L. , Patel, Vijay A. , Polster, Sean P. , Brandel, Michael G , Sato, Mariko , Patel, Vijay A , Polster, Sean P , Hsia, Beau , Faraji, Farhoud , Crawford, John Ross

Cancers | February 5, 2025 | Volume: 17 | Issue: 3 | Pages: 536

10.3390/cancers17030536 | PMID 39941902 Get It

Background: Chordoma is a rare primary tumor originating from embryonic notochord remnants, with limited systemic therapeutic options due to a poor understanding of its genomic landscape. This study aims to characterize the genetic alterations in chordoma using a large national patient-level genomic repository, the AACR Project GENIE, to identify potential therapeutic targets and improve disease modeling. Methods: A retrospective analysis of chordoma samples was conducted using the AACR Project GENIE database. Targeted sequencing data were analyzed for recurrent somatic mutations, tumor mutational burden, and chromosomal copy number variations, with significance set at p < 0.05. Results: Frequent mutations were observed in genes associated with SWI/SNF complex affecting chromatin remodeling (SETD2, PBRM1, ARID1A). Mutations were also common among the TERT promoter regions, and cell cycle regulation (CDKN2A). Significant co-occurrences were identified among PBRM1, BRCA2, and KMT2D mutations. CDKN2A/B deletions were enriched in metastatic tumors, and pediatric cases demonstrated distinct mutation profiles compared to adults. Conclusions: This study provides a genomic profile of chordoma, identifying key mutations and potential therapeutic targets. These findings highlight the roles of chromatin remodeling and cell cycle pathways in chordoma biology, offering insights for future precision medicine approaches and therapeutic interventions.
Surgical Adverse Events for Primary Tumors of the Spine and Their Impact on Outcomes: An Observational Study From the Primary Tumors Research and Outcomes Network
Laflamme, Mathieu, Rhines, Laurence D. , Gokaslan, Ziya L. , Reynolds, Jeremy , Disch, Alexander C. , Chou, Dean , Feng, Wei , Rampersaud, Y. Raja, Lord, Elizabeth L. , Sciubba, Daniel M. , Laufer, Ilya , Sahgal, Arjun , Fisher, Charles G. , Dea, Nicolas , Tumor, on behalf of the AO Spine Knowledge Forum, Reynolds, Jeremy , Dea, Nicolas , Reynolds, Jeremy , Laflamme, Mathieu , Gasbarrini, Alessandro , Lazáry, Áron , Luzzati, Alessandro , Clarke, Michelle J. , Wei, Feng, Bettegowda, Chetan , Boriani, Stefano , Shin, John H. , Tumor, on behalf of the AO Spine Knowledge Forum

Neurosurgery | February 5, 2025 | Volume: 97 | Issue: 1 | Pages: 264-276

10.1227/neu.0000000000003369 | PMID 39907438 Get It

BACKGROUND AND OBJECTIVES: Aggressive resection for primary tumors of the spine are associated with a high rate of adverse events (AEs), but the impact of AEs on patient-reported outcomes (PROs) remains unknown and is critical to the shared decision-making. Our primary objective was to assess the impact of surgical AEs on PROs using an international registry. Assessing the impact on clinical outcomes and identifying risk factors for AEs were our secondary objectives. METHODS: Patients who underwent surgery for a primary spinal tumor were selected through the Primary Tumor Research and Outcomes Network. Our primary outcome was the impact of AEs on PROs at 3 and 12 months after surgery (measured with Spinal Oncology Study Group Outcomes Questionnaire, Short-Form 36, and EuroQol 5 Dimension). We also assessed the impact on clinical outcomes (local control, surgical margins, readmission, reoperation, and mortality). We stratified our results according to severity of AEs, histology, and type of resection. RESULTS: 374 patients met inclusion criteria (219 males/155 females). The mean age of the cohort was 48.7 years. The most frequent histology was chordoma (37.3%) followed by chondrosarcoma (8.8%). Sixty-seven patients (17.9%) experienced at least 1 intraoperative AE and 117 patients (31.3%) had at least 1 postoperative AE within 3 months. Overall, 159 patients (42.5%) experienced AEs. The readmission rate was significantly higher in patients who experienced AEs (Any AE: 10.1% vs no AE: 1.9% within 3 months; P = <0.001). PROs were not significantly affected by AEs in most questionnaires. Local control, risk of reoperation, mortality, and achieving preplanned margins were similar between AE groups. CONCLUSION: The rate of surgical AEs is considerable in this population. Surgical AEs seem to be associated with a higher number of readmissions, but do not seem to result in significant differences in PROs or in a higher risk of reoperation, mortality, and failure to achieve preplanned margins.
A Global Perspective on Metabolically Driven Primary Liver Cancer: Opportunities and Challenges
Ahn, Joseph , Ahn, Joseph C

American Journal of Gastroenterology | February 5, 2025 | Volume: 120 | Issue: 10 | Pages: 2240-2241

10.14309/ajg.0000000000003282 | PMID 39907254 Get It

Prevalence and Patterns of Opioid Use in Chronic Pancreatitis
Phillips, Anna Evans , Conwell, Darwin L. , Li, Shuang , Saloman, Jami L. , Hart, Phil A. , Fogel, Evan L. , Vege, Santhi Swaroop, Andersen, Dana K. , Fisher, William E., Forsmark, Christopher E., Park, Walter G. , Topazian, Mark , Yadav, Dhiraj , Saloman, Jami L , Vege, Santhi Swaroop , Pandol, Stephen J. , Van Den Eeden, Stephen K , Serrano, José , Li, Liang

Clinical and Translational Gastroenterology | February 5, 2025 | Volume: 16 | Issue: 5 | Pages: e00807

10.14309/ctg.0000000000000807 | PMID 39907252 Get It

INTRODUCTION: Opioids are used to treat pain in chronic pancreatitis (CP), but little is known about current use patterns. The aim of this study was to characterize the utilization of opioids and associations with clinical characteristics in adult patients with CP. METHODS: This cross-sectional analysis used baseline data from participants with definite CP enrolled in a cohort study in the United States (PROspective Evaluation of CP for EpidEmiologic and Translational StuDies). Data on demographics, pain medication use, healthcare utilization, disability, and pain patterns were systematically collected in case report forms while quality of life was assessed with patient-reported outcome instruments. Opioid use was classified according to strength (weak or strong) and frequency (scheduled or as-needed). RESULTS: A total of 681 participants (n = 364, 53% male) were included: 299 (44%) were current opioid users (22% only weak opioids and 22% at least 1 strong opioid). Increasing frequency and severity of pain was associated with increase of weak, strong, as-needed, or scheduled opioids. Neuromodulators were used by ∼40% of participants; increasing use was associated with increasing frequency and severity of pain. On multivariate analysis, independent predictors associated with strength and frequency of current opioid use were pain patterns (odds ratios [ORs] 1.84–8.32 and ORs 1.92–8.52, respectively, P < 0.001) and prior celiac plexus block (OR 3.54, 95% confidence intervals 1.82–6.87 and OR 3.42, 95% confidence intervals 1.76–6.64, respectively). Participants using opioids had higher prevalence of disability, healthcare utilization, and poorer quality of life. DISCUSSION: Opioid use in CP is common and associated with increased pain severity and constancy. These data provide foundational estimates for future trials that can elucidate the complex interactions between patient factors, pain, and interventions.
Amplification of Higher-Order Salivary Gland Volume Effects from External Beam Radiotherapy in Normal Tissue Complication Probability Modeling of Radiopharmaceutical Therapy
Gu, Chunming , Kiess, Ana P. , Lee, Junghoon , McNutt, Todd , Quon, Harry , Xin, Zhuoyao, Yusufaly, Tahir , Quon, Harry , Gu, Chunming , Hobbs, Robert F

Radiation | February 5, 2025 | Volume: 5 | Issue: 1 | Pages: 8

10.3390/radiation5010008 Get It

Salivary glands are common organs at risk in both head and neck external beam radiotherapy (EBRT) and radiopharmaceutical therapy (RPT), but incidences of xerostomia in RPT are inconsistent with the EBRT Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) limits. In EBRT, salivary glands are usually assumed to be parallel organs, with QUANTEC guidelines based on Dmean, but this is known to be a gross over-simplification of the full complexity of the underlying functional organization. The goal of this work is to combine machine learning of EBRT dose–outcome data with stylized small-scale RPT dosimetry to discover more reliable normal tissue complication probability (NTCP) models of xerostomia across both modalities. A retrospective cohort of 211 EBRT patients was analyzed using a custom-designed in-house machine learning workflow. From this, a hierarchy of three models of increasing complexity was trained, evaluated for performance and generalization, and coupled with stylized small-scale salivary gland dosimetry to assess the influence of model complexity on the predicted NTCP for plausible patterns of RPT dose nonuniformity. The three models in the hierarchy (A, B, C), in increasing order of complexity, associate xerostomia with the following: the mean dose to the whole contralateral parotid (model A), the mean dose to a ductally localized region (model B) and a serial interaction dose term between two ductal sub-compartments (model C). While the difference between the three models for EBRT p-values and AUCs is rather marginal, for physiologically driven ductal dose distributions in RPT, the predicted reduction in TD50 can be as large as a factor of 10. These results provide hints towards a plausible reconciliation of the observed inconsistency of xerostomia in RPT with EBRT dose limits.
Rare Cardiac Duo: Double Orifice Mitral Valve and Bicuspid Aortic Valve
Tsai, Chieh-Mei , Michelena, Héctor I. , Padang, Ratnasari , Pislaru, Sorin V. , Niaz, Talha , Nkomo, Vuyisile T. , Sabbah, Michael S. , Nkomo, Vuyisile T , Michelena, Hector I , Niaz, Talha

Circulation: Cardiovascular Imaging | February 5, 2025 | Volume: 18 | Issue: 7 | Pages: No page available

10.1161/circimaging.124.017602 | PMID 39906992 Get It

Cholecystitis as a result of cecal herniation through the foramen of Winslow
Schimmel, McKenna L , Mirande, Maxwell D, Khan, Fazal Wahab , Heller, Stephanie F. , Stephens, Daniel , Khan, Fazal W, Schimmel, McKenna L , Mirande, Maxwell D. , Stephens, Daniel

Journal of Surgical Case Reports | February 5, 2025 | Volume: 2025 | Issue: 2 | Pages: No page available

10.1093/jscr/rjaf060 | PMID 39975848 Get It

Abstract Internal herniation through the foramen of Winslow is one of the rarest types of hernia. As signs and symptoms can be quite generalized, prompt identification can prove difficult, leading to increased morbidity and mortality. The majority of reported cases of foramen of Winslow herniation result in obstruction of either the small or large bowel requiring operative intervention. As they are so rare, there is no established treatment algorithm for foramen of Winslow hernias. We present here a unique case of cecal herniation through the foramen of Winslow resulting in biliary compression and acute cholecystitis without bowel obstruction that was managed with laparoscopic cholecystectomy and right hemicolectomy.
Can Galectin-3 Be Used as a Predictor of Obstructive Sleep Apnea Severity: Insights from High-Volume Patient Single Center
Brajković, Milica , Nikolić, Sofija , Popadić, Višeslav , Rajović, Nina , Nikolić, Novica , Sekulić, Ana , Stjepanović, Mihailo , Popević, Spasoje , Zdravković, Marija , Nikolic, Novica , Brankovic, Marija , Stjepanovic, Mihailo , Popevic, Spasoje , Zdravkovic, Marija , Popadic, Viseslav , Rajovic, Nina , Milić, Nataša , Branković, Marija , Milovanovic, Branko

Diagnostics | February 5, 2025 | Volume: 15 | Issue: 3 | Pages: 375

10.3390/diagnostics15030375 | PMID 39941305 Get It

Background/Objectives: Obstructive sleep apnea (OSA) is a condition characterized by intermittent airway obstructions, leading to reduced oxygen levels and increased sympathetic nervous system activity. OSA can cause a range of health problems, including an increased risk of cardiovascular diseases and mortality. Galectin-3, a member of the galectin family, plays a significant role in inflammation and fibrosis, and studies show that it is elevated in various conditions, including heart and lung diseases. The aim of this study was to determine whether galectin-3 levels are related to the severity of sleep apnea. Methods: A total of 191 participants from the University Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia, between January 2023 and May 2024, were included in the analyses. All patients were hospitalized under suspicion of OSA, and they all underwent a polysomnography test. Various demographic, respiratory, laboratory, and clinical parameters were obtained. Correlations between numerical variables and galectin-3 were assessed by the Pearson or Spearman correlation coefficients. Univariate and multivariate linear regression models were used to assess the predictors of galectin-3 values. In all analyses, the significance level was set at 0.05. Results: The mean age of the study participants was 56.2 years, mostly male (68.9%). Of the comorbidities, two-thirds of patients had hypertension (66.1%), 46.8% had hyperlipoproteinemia, and 21.1% had diabetes mellitus. Patients who had an AHI of more than fifteen events per hour more often had higher values of galectin-3. OSA severity had a significant positive correlation with galectin-3 (p = 0.014). In multivariate linear regression analysis, significant independent predictors of higher galectin-3 values were older age, presence of coronary disease, hypoventilation syndrome, higher BMI, NTproBNP, lactate, creatinine, lower LDL, and lower FEV1 (p < 0.05). Conclusions: The present study demonstrated that galectin-3 is linked to the severity of OSA and plays a crucial role in inflammation induced by intermittent hypoxia in OSA. Further screening and interventions targeting galectin-3 could aid in preventing inflammatory diseases related to sleep disturbances.